Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies-Reference-Cited by-同舟云学术

Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies

Published:2024-05-21 Issue:7-8 Volume:405 Page:485-515
ISSN:1431-6730
Container-title:Biological Chemistry
language:en
Short-container-title:

Author:

Tsiverioti Christina Angeliki¹^ORCID,Gottschlich Adrian¹²³^ORCID,Trefny Marcel¹^ORCID,Theurich Sebastian²³⁴⁵^ORCID,Anders Hans-Joachim⁶^ORCID,Kroiss Matthias⁶⁷⁸^ORCID,Kobold Sebastian¹⁴⁹^ORCID

Affiliation:

1. Division of Clinical Pharmacology , University Hospital, LMU Munich , Lindwurmstr. 2a, 80337 Munich , Germany

2. Department of Medicine III , University Hospital, LMU Munich , Marchioninstr. 15, 81377 Munich , Germany

3. Bavarian Cancer Research Center (BZKF), LMU Munich , Pettenkoferstr. 8a, 80336 Munich , Germany

4. 74939 German Cancer Consortium (DKTK), Partner Site Munich, A Partnership Between DKFZ and University Hospital of the LMU , Marchioninstr. 15, 81377 Munich , Germany

5. Cancer and Immunometabolism Research Group , 74939 Gene Center LMU , Feodor-Lynen Str. 25, 81377 Munich , Germany

6. Department of Medicine IV , University Hospital, LMU Munich , Ziemssenstr. 5, 80336 Munich , Germany

7. Division of Endocrinology and Diabetes, Department of Medicine , University Hospital, University of Würzburg , Josef-Schneider-Str, 9780 Würzburg , Germany

8. Comprehensive Cancer Center Mainfranken , University of Würzburg , Josef-Schneider-Str. 6, 9780 Würzburg , Germany

9. Einheit für Klinische Pharmakologie (EKLiP) , Helmholtz Zentrum München – German Research Center for Environmental Health , Ingolstädter Landstr. 1, D-85764 Neuherberg , Germany

Abstract

Abstract Chimeric antigen receptor (CAR)-T cell therapy has led to remarkable clinical outcomes in the treatment of hematological malignancies. However, challenges remain, such as limited infiltration into solid tumors, inadequate persistence, systemic toxicities, and manufacturing insufficiencies. The use of alternative cell sources for CAR-based therapies, such as natural killer cells (NK), macrophages (MΦ), invariant Natural Killer T (iNKT) cells, γδT cells, neutrophils, and induced pluripotent stem cells (iPSC), has emerged as a promising avenue. By harnessing these cells’ inherent cytotoxic mechanisms and incorporating CAR technology, common CAR-T cell-related limitations can be effectively mitigated. We herein present an overview of the tumoricidal mechanisms, CAR designs, and manufacturing processes of CAR-NK cells, CAR-MΦ, CAR-iNKT cells, CAR-γδT cells, CAR-neutrophils, and iPSC-derived CAR-cells, outlining the advantages, limitations, and potential solutions of these therapeutic strategies.

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/hsz-2023-0317/pdf

Reference233 articles.

1. Abe, Y., Muto, M., Nieda, M., Nakagawa, Y., Nicol, A., Kaneko, T., Goto, S., Yokokawa, K., and Suzuki, K. (2009). Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp. Hematol. 37: 956–968, https://doi.org/10.1016/j.exphem.2009.04.008.

2. Aehnlich, P., Carnaz Simões, A.M., Skadborg, S.K., Holmen Olofsson, G., and Thor Straten, P. (2020). Expansion with IL-15 increases cytotoxicity of Vγ9Vδ2 T cells and is associated with higher levels of cytotoxic molecules and T-bet. Front. Immunol. 11: 1868, https://doi.org/10.3389/fimmu.2020.01868.

3. Akira, S., Takeda, K., and Kaisho, T. (2001). Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2: 675–680, https://doi.org/10.1038/90609.

4. Albinger, N., Pfeifer, R., Nitsche, M., Mertlitz, S., Campe, J., Stein, K., Kreyenberg, H., Schubert, R., Quadflieg, M., Schneider, D., et al.. (2022). Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia. Blood Cancer J. 12: 61, https://doi.org/10.1055/s-0042-1748710.

5. Alcantara, M., Tesio, M., June, C.H., and Houot, R. (2018). CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. Leukemia 32: 2307–2315, https://doi.org/10.1038/s41375-018-0285-8.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Highlight: new developments in immunoengineering;Biological Chemistry;2024-06-21